EuBiologics secures 29.8B KRW cholera vaccine contract
유바이오로직스
206650
Signal Score
Historical Avg Return (5d)
+0.36%
Data Coverage
100%n=677
Risk-adjusted indicator based on 677 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Amount: 29,794,432,962 KRW (USD 19,659,804)
- • Percentage of Recent Revenue: 19.97%
- • Contract Period: June 15, 2026 - August 14, 2026
- • Recent Annual Revenue (2025): 149,195,024,704 KRW
AI Analysis Summary
EuBiologics Co., Ltd. announced a single sales and supply contract with UNICEF for oral cholera vaccines (Euvichol/Euvichol-S) valued at 29,794,432,962 KRW (USD 19,659,804). This contract represents 19.97% of the company's recent annual revenue of 149,195,024,704 KRW (based on 2025 separate financial statements). The contract period is from June 15, 2026, to August 14, 2026, with payment due within 30 days after submission of supporting documents. This is a recurring contract with UNICEF, indicating a stable revenue stream. The significant contract value relative to revenue is a positive for future earnings.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.